Finance

Form 424B5 Nkarta Inc For: 3 April

https://www.investing.com/news/filings/form-424b5-nkartainc-for-3-april-93CH-4597392 Investing.com

Mobix Labs enters $3 million convertible note agreement with Leviston Resources

https://www.investing.com/news/sec-filings/mobix-labs-enters-3-million-convertible-note-agreement-with-leviston-resources-93CH-4597398 Investing.com

PubMatic (PUBM) general counsel Woods sells $46,669 in stock

https://www.investing.com/news/insider-trading-news/pubmatic-pubm-general-counsel-woods-sells-46669-in-stock-93CH-4597393 Investing.com

What is NMN: Everything you need to know from Experts

:m-0 :text-accent pb-1 font-graphik-compact font-semibold text-primary-hover **:text-primary-hover group-focus-within:text-accent md:group-focus-within:stroke-accent group-open:stroke-accent **:no-underline!">What are NMN supplements? NMN (nicotinamide mononucleotide) supplements provide your body with a precursor...

Mastech Digital awards CEO Nirav Patel 100,314 restricted shares as 2025 bonus

https://www.investing.com/news/sec-filings/mastech-digital-awards-ceo-nirav-patel-100314-restricted-shares-as-2025-bonus-93CH-4597363 Investing.com

What is NMN: Everything you need to know from Experts

:m-0 :text-accent pb-1 font-graphik-compact font-semibold text-primary-hover **:text-primary-hover group-focus-within:text-accent md:group-focus-within:stroke-accent group-open:stroke-accent **:no-underline!">What are NMN supplements? NMN (nicotinamide mononucleotide) supplements provide your body with a precursor...

Wayfair’s Blotner sells $345k in shares

https://www.investing.com/news/insider-trading-news/wayfairs-blotner-sells-345k-in-shares-93CH-4597336 Investing.com

Down Arrow Button Icon

:m-0 :text-accent pb-1 font-graphik-compact font-semibold text-primary-hover **:text-primary-hover group-focus-within:text-accent md:group-focus-within:stroke-accent group-open:stroke-accent **:no-underline!">What are NMN supplements? NMN (nicotinamide mononucleotide) supplements provide your body with a precursor...

AbbVie reports $744 million IPR&D expense for Q1, updates 2026 earnings guidance

https://www.investing.com/news/sec-filings/abbvie-reports-744-million-iprd-expense-for-q1-updates-2026-earnings-guidance-93CH-4597303 Investing.com

Latest articles

spot_imgspot_img